Sequitur Inc

Sequitur's proprietary antisense and RNAi technologies are being developed as therapeutic compounds that specifically inhibit gene expression and are employed for gene function and target validation research. Sequitur also offers a line of products and services relating to detecting gene expression.

Further Information: http://www.sequiturinc.com/